Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course
Indian Firm Awaiting Market To Open Up In FY2025
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
